HK1182383A1 - 激酶抑制劑的結晶形式 - Google Patents

激酶抑制劑的結晶形式

Info

Publication number
HK1182383A1
HK1182383A1 HK13109690.9A HK13109690A HK1182383A1 HK 1182383 A1 HK1182383 A1 HK 1182383A1 HK 13109690 A HK13109690 A HK 13109690A HK 1182383 A1 HK1182383 A1 HK 1182383A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
crystalline forms
crystalline
forms
kinase
Prior art date
Application number
HK13109690.9A
Other languages
English (en)
Inventor
Geoff G Z Zhang
Paul J Brackemeyer
Ahmad Y Sheikh
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of HK1182383A1 publication Critical patent/HK1182383A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK13109690.9A 2010-06-09 2013-08-20 激酶抑制劑的結晶形式 HK1182383A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35317010P 2010-06-09 2010-06-09
PCT/US2011/039603 WO2011156473A1 (en) 2010-06-09 2011-06-08 Crystalline forms of kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1182383A1 true HK1182383A1 (zh) 2013-11-29

Family

ID=44454074

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13109690.9A HK1182383A1 (zh) 2010-06-09 2013-08-20 激酶抑制劑的結晶形式

Country Status (9)

Country Link
US (1) US8633317B2 (zh)
EP (1) EP2580221B1 (zh)
JP (1) JP5727599B2 (zh)
CN (1) CN103003283A (zh)
CA (1) CA2802042A1 (zh)
ES (1) ES2559212T3 (zh)
HK (1) HK1182383A1 (zh)
MX (1) MX2012014386A (zh)
WO (1) WO2011156473A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181195A (zh) * 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE
CN111718343A (zh) * 2015-12-08 2020-09-29 浙江亚太药业股份有限公司 一种吡啶衍生物的t晶型及其制备方法、用途
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
EP1968979A2 (en) * 2005-12-08 2008-09-17 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
US8729268B2 (en) * 2008-03-05 2014-05-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
MY179042A (en) 2008-12-05 2020-10-26 Abbvie Bahamas Ltd Kinase inhibitors with improved cyp safety profile

Also Published As

Publication number Publication date
CA2802042A1 (en) 2011-12-15
EP2580221B1 (en) 2015-10-21
MX2012014386A (es) 2013-05-01
WO2011156473A1 (en) 2011-12-15
ES2559212T3 (es) 2016-02-11
JP5727599B2 (ja) 2015-06-03
EP2580221A1 (en) 2013-04-17
JP2013528222A (ja) 2013-07-08
US8633317B2 (en) 2014-01-21
US20120203002A1 (en) 2012-08-09
CN103003283A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
HK1259135A1 (zh) Vmat2的苯並喹啉酮抑制劑
ZA201208373B (en) Compounds useful as inhibitors of atr kinase
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
HK1200828A1 (zh) 激酶抑制劑
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
ZA201204136B (en) Pteridinones as inhibitors of polo-like kinase
HK1177205A1 (zh) 惡唑的激酶抑制劑
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
PL2710007T3 (pl) Inhibitory kinazy
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
IL225605A0 (en) Polo-like kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
IL229028A0 (en) Kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1199873A1 (zh) 激酶抑制劑
IL220187A0 (en) Inhibitors of sphingosine kinase
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
HK1182383A1 (zh) 激酶抑制劑的結晶形式
EP2531197A4 (en) SOLID FORMS OF MACROCYCLIC CHINESE INHIBITORS
ZA201300009B (en) Oral formulation of kinase inhibitors
HK1182384A1 (zh) 激酶抑制劑的結晶形式
HK1179255A1 (zh) 激酶抑制劑的晶體形式
GB201009730D0 (en) Kinase inhibitor compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200607